Treatment of high Trop-2-expressing triple-negative breast cancer (TNBC) with sacituzumab govitecan (IMMU-132) overcomes homologous recombination repair (HRR) rescue mediated by Rad51

被引：5
|
作者：
Cardillo, Thomas M.
Mostafa, Ali A.
Rossi, Diane L.
Liu, Donglin
Chang, Chien-Hsing
Sharkey, Robert M.
Goldenberg, David M.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-3193
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3193
引用
收藏
页数：2
相关论文
共 20 条
  • [1] Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
    Bardia, Aditya
    Mayer, Ingrid A.
    Diamond, Jennifer R.
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Starodub, Alexander N.
    Shah, Nikita C.
    O'Shaughnessy, Joyce
    Kalinsky, Kevin
    Guarino, Michael
    Abramson, Vandana
    Juric, Dejan
    Tolaney, Sara M.
    Berlin, Jordan
    Messersmith, Wells A.
    Ocean, Allyson J.
    Wegener, William A.
    Maliakal, Pius
    Sharkey, Robert M.
    Govindan, Serengulam V.
    Goldenberg, David M.
    Vahdat, Linda T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) : 2141 - +
  • [2] Significant enhancement of efficacy of an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), in experimental triple-negative breast cancer (TNBC) when combined with microtubule or PARP inhibitors
    Cardillo, Thomas M.
    Govindan, Serengulam V.
    Zalath, Maria
    Mostafa, Ali
    Arrojo, Roberto
    Sharkey, Robert M.
    Goldenberg, David M.
    CANCER RESEARCH, 2016, 76
  • [3] Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer (NeoSTAR)
    Spring, Laura M.
    Tolaney, Sara M.
    Desai, Neelam
    Comander, Amy
    Mulvey, Therese
    Krop, Ian E.
    Winer, Eric P.
    Mittendorf, Elizabeth A.
    Ellisen, Leif W.
    Bardia, Aditya
    CANCER RESEARCH, 2021, 81 (04)
  • [4] A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC)
    Bardia, Aditya
    Rugo, Hope S.
    Horne, Heather
    Wegener, William A.
    Goldenberg, David M.
    O'Shaughnessy, Joyce
    CANCER RESEARCH, 2018, 78 (04)
  • [5] Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
    Jung Ok Lee
    Min Ju Kang
    Won Seok Byun
    Shin Ae Kim
    Il Hyeok Seo
    Jeong Ah. Han
    Ji Wook Moon
    Ji Hae Kim
    Su Jin Kim
    Eun Jung Lee
    Serk In Park
    Sun Hwa Park
    Hyeon Soo Kim
    Breast Cancer Research, 21
  • [6] Metformin overcomes resistance to cisplatin in triple-negative breast cancer (TNBC) cells by targeting RAD51
    Lee, Jung Ok
    Kang, Min Ju
    Byun, Won Seok
    Kim, Shin Ae
    Seo, Il Hyeok
    Han, Jeong Ah
    Moon, Ji Wook
    Kim, Ji Hae
    Kim, Su Jin
    Lee, Eun Jung
    Park, Serk In
    Park, Sun Hwa
    Kim, Hyeon Soo
    BREAST CANCER RESEARCH, 2019, 21 (01)
  • [7] Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience
    Bardia, Aditya
    Vahdat, Linda T.
    Diamond, Jennifer Robinson
    Starodub, Alexander
    Moroose, Rebecca L.
    Isakoff, Steven J.
    Ocean, Allyson J.
    Berlin, Jordan
    Messersmith, Wells A.
    Thomas, Sajeve Samuel
    Wilhelm, Francois
    Wegener, William A.
    Maliakal, Pius P.
    Sharkey, Robert M.
    Goldenberg, David M.
    Mayer, Ingrid A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC): Updated results
    Bardia, A.
    Diamond, J. R.
    Mayer, I. A.
    Isakoff, S. J.
    Abramson, V.
    Starodub, A. N.
    O'Shaughnessy, J.
    Kalinsky, K.
    Moroose, R.
    Shah, N.
    Juric, D.
    Shapiro, G. I.
    Guarino, M.
    Ocean, A. J.
    Messersmith, W. A.
    Berlin, J. D.
    Wegener, W. A.
    Sharkey, R. M.
    Goldenberg, D. M.
    Vahdat, L. T.
    CANCER RESEARCH, 2017, 77
  • [9] Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.
    Spring, Laura
    Tolaney, Sara M.
    Desai, Neelam Vijay
    Fell, Geoffrey
    Trippa, Lorenzo
    Comander, Amy H.
    Mulvey, Therese Marie
    McLaughlin, Shannon
    Ryan, Phoebe
    Rosenstock, Aron S.
    Garrido-Castro, Ana Christina
    Lynce, Filipa
    Moy, Beverly
    Isakoff, Steven J.
    Tung, Nadine M.
    Mittendorf, Elizabeth A.
    Ellisen, Leif W.
    Bardia, Aditya
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [10] Detection of homologous recombination repair deficiency (HRD) in treatment-naive early triple-negative breast cancer (TNBC) by RAD51 foci and comparison with DNA-based tests
    Serra Elizalde, V.
    Llop-Guevara, A.
    Pearson, A.
    Cruz, C.
    Castroviejo-Bermejo, M.
    Chopra, N.
    Tovey, H.
    Toms, C.
    Kriplani, D.
    Gevensleben, H.
    Roylance, R.
    Chan, S.
    Tutt, A.
    Skene, A.
    Evans, A.
    Davies, H. R.
    Bliss, J.
    Nik-Zainal, S.
    Balmana, J.
    Turner, N.
    ANNALS OF ONCOLOGY, 2021, 32 : S21 - S22
12